Sun, Dec 22, 2024
| فارسی
Volume 30, Issue 1 (Continuously Updated 2024)
IJPCP 2024, 30(1): 0-0 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Moshtaghi E, Bayazi M H, Rigi Koote B. Comparing the Effects of CBT Plus tDCS or Pharmacotherapy on Depressive Symptoms, Inhibition, and Cognitive Flexibility in Stroke Patients: A Randomized Clinical Trial. IJPCP 2024; 30 (1)
URL: http://ijpcp.iums.ac.ir/article-1-4070-en.html
URL: http://ijpcp.iums.ac.ir/article-1-4070-en.html
1- Department of Psychology, Torbat-e Jam branch, Islamic Azad University, Torbat-e Jam, Iran.
2- Department of Psychology, Torbat-e Jam branch, Islamic Azad University, Torbat-e Jam, Iran. ,brkpsycho1988@gmail.com
3- Department of Clinical Psychology, Child and Adolescent Health Research Center, Zahedan University of Medical Sciences, Zahedan, Iran.
2- Department of Psychology, Torbat-e Jam branch, Islamic Azad University, Torbat-e Jam, Iran. ,
3- Department of Clinical Psychology, Child and Adolescent Health Research Center, Zahedan University of Medical Sciences, Zahedan, Iran.
Abstract: (543 Views)
Objectives The present study aims to compare the effects of cognitive-behavioral therapy (CBT) plus transcranial direct current stimulation (tDCS) or pharmacotherapy on depression symptoms, inhibition and cognitive flexibility of stroke patients
Methods This is a randomized controlled clinical trial with a pre-test/post-test/follow-up design. The study population consists of all stroke sufferers referred to Dr. Hashemzehi's clinic in Zahedan, south of Iran, in 2022. The samples were 45 eligible patients who were selected by a convenience sampling method and randomly divided into three groups of 15 including CBT+tDCS, CBT+pharmacotherapy, and control. To measure depression, inhibition, and cognitive flexibility, we used Beck’s depression inventory, go/no go test, and Stroop test in the pre-test, post-test, and 2-month follow-up phases. The CBT was provided at 12 sessions according to Kootker et al.'s CBT protocol for stroke patients. The tDCS program was 20 sessions of anodal stimulation over the left dorsolateral prefrontal cortex. The pharmacotherapy was the administration of 10 mg citalopram daily for three weeks.
Results The results indicated the short-term and long-term effectiveness of both CBT+tDCS and CBT + pharmacotherapy in reducing depression symptoms (P<0.05), and there was no significant difference between their effectiveness of . Only the CBT+tDCS had a short-term effect on improving inhibition and cognitive flexibility.
Conclusion Both CBT+tDCS and CBT+pharmacotherapy (10 mg citalopram) can be useful for reducing depression symptoms in stroke sufferers.
Methods This is a randomized controlled clinical trial with a pre-test/post-test/follow-up design. The study population consists of all stroke sufferers referred to Dr. Hashemzehi's clinic in Zahedan, south of Iran, in 2022. The samples were 45 eligible patients who were selected by a convenience sampling method and randomly divided into three groups of 15 including CBT+tDCS, CBT+pharmacotherapy, and control. To measure depression, inhibition, and cognitive flexibility, we used Beck’s depression inventory, go/no go test, and Stroop test in the pre-test, post-test, and 2-month follow-up phases. The CBT was provided at 12 sessions according to Kootker et al.'s CBT protocol for stroke patients. The tDCS program was 20 sessions of anodal stimulation over the left dorsolateral prefrontal cortex. The pharmacotherapy was the administration of 10 mg citalopram daily for three weeks.
Results The results indicated the short-term and long-term effectiveness of both CBT+tDCS and CBT + pharmacotherapy in reducing depression symptoms (P<0.05), and there was no significant difference between their effectiveness of . Only the CBT+tDCS had a short-term effect on improving inhibition and cognitive flexibility.
Conclusion Both CBT+tDCS and CBT+pharmacotherapy (10 mg citalopram) can be useful for reducing depression symptoms in stroke sufferers.
Keywords: Cognitive-behavioral therapy, Pharmacotherapy, Citalopram, depression, Inhibition, cognitive flexibility, Stroke
Type of Study: Original Research |
Subject:
Psychiatry and Psychology
Received: 2023/12/4 | Accepted: 2024/08/10 | Published: 2024/07/31
Received: 2023/12/4 | Accepted: 2024/08/10 | Published: 2024/07/31
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright © The Author(s);
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
